Zymeworks Inc. (ZYME): Shareholders' Equity
$268.50M
As of 2025-12-31
$80.37M
As of 2026-06-30
-18.3%
3-year compound annual growth
-8.1%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $268.50M | -20.7% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $338.77M | -27.1% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $464.81M | -5.7% | 2026-03-02, Balance as of period end |
| 2022-12-31 | $492.96M | +97.9% | 2025-03-05, Balance as of period end |
| 2021-12-31 | $249.09M | -39.2% | 2024-03-06, Balance as of period end |
| 2020-12-31 | $409.92M | n/a | 2023-03-07, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Zymeworks Inc. (ZYME) | 2025-12-31 | $268.50M | -20.7% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $154.66M | +289.9% |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $296.72M | +69.0% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | -$105.47M | n/m |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $106.03M | +67.5% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $198.82M | -7.9% |
| Xencor Inc (XNCR) | 2025-12-31 | $635.59M | -6.2% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | -$659.62M | n/m |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $1.34M | -88.2% |
Compare ZYME, ZVRA, TBPH, URGN side by side · Screen every company in Pharmaceutical Preparations ↗